ENTA Key Statistics, Chart & Performance
The current stock price of ENTA is 13.89 USD. In the past month the price decreased by -2.05%. In the past year, price increased by 172.89%.
ENTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.86B |
Related stock screener links
About ENTA
Company Profile
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 120 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The firm has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The firm also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Company Info
ENANTA PHARMACEUTICALS INC
4 Kingsbury Avenue
Watertown MASSACHUSETTS 02472 US
CEO: Jay R. Luly
Employees: 120
Phone: 16176070800
ENANTA PHARMACEUTICALS INC / ENTA FAQ
What does ENTA do?
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 120 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The firm has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The firm also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Can you provide the latest stock price for ENANTA PHARMACEUTICALS INC?
The current stock price of ENTA is 13.89 USD. The price increased by 2.28% in the last trading session.
What is the dividend status of ENANTA PHARMACEUTICALS INC?
ENTA does not pay a dividend.
How is the ChartMill rating for ENANTA PHARMACEUTICALS INC?
ENTA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does ENANTA PHARMACEUTICALS INC belong to?
ENANTA PHARMACEUTICALS INC (ENTA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for ENANTA PHARMACEUTICALS INC?
ENANTA PHARMACEUTICALS INC (ENTA) has a market capitalization of 400.87M USD. This makes ENTA a Small Cap stock.
Can you provide the ownership details for ENTA stock?
You can find the ownership structure of ENANTA PHARMACEUTICALS INC (ENTA) on the Ownership tab.
ENTA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ENTA. When comparing the yearly performance of all stocks, ENTA is one of the better performing stocks in the market, outperforming 97.18% of all stocks.
ENTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ENTA. Both the profitability and financial health of ENTA have multiple concerns.
ENTA Financial Highlights
Over the last trailing twelve months ENTA reported a non-GAAP Earnings per Share(EPS) of -3.83. The EPS increased by 30.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.17% | ||
| ROE | -126.53% | ||
| Debt/Equity | 1.74 |
ENTA Forecast & Estimates
14 analysts have analysed ENTA and the average price target is 19.51 USD. This implies a price increase of 40.44% is expected in the next year compared to the current price of 13.89.
For the next year, analysts expect an EPS growth of 18.3% and a revenue growth -2.24% for ENTA